- Astex Pharmaceuticals' (ASTX) SGI-110 "showed clear activity in patients with acute myeloid leukemia" in Phase II testing.
- The overall remission rate in 67 subjects was 25%.
- However, no results were provided for patients with Myelodysplastic syndromes (MDS), a group of blood and bone marrow disorders, who were also part of the trial.
- Shares +12.2%.
Astex's SGI-110 shows "clear activity" in leukemia patients
Aug 28 2013, 07:37 ET